Table 1 Overview of basic characteristics of CVOTs terminated in 2015 and published in 2016
| Â | Study status | Drug | Drug class | Intervention | Primary outcome | N | Follow-up (years) | Start and estimated end date | Clinicaltrials.gov ID |
|---|---|---|---|---|---|---|---|---|---|
EMPA-REG | Completed | Empagliflozin | SGLT-2 inhibitor | Empagliflozin 10Â mg versus empagliflozin 25Â mg versus placebo | CV death, MI, or stroke | 7000 | 3.1 | 07.2010 to 04.2015 | NCT01131676 |
LEADER | Completed | Liraglutide | GLP-1 inhibitor | Liraglutide versus placebo | CV death, MI, or stroke | 9340 | 3.8 | 08.2010 to 12.2015 | NCT01179048 |
SUSTAIN-6 | Completed | Semaglutide | GLP-1 inhibitor | Semaglutide 0.5Â mg versus semaglutide 1.0Â mg versus placebo | CV death, MI, or stroke | 3299 | 1.99 | 02.2013 to 01.2016 | NCT01720446 |